Ramin Goudarzi, MBA is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ramin Goudarzi is a clinical pharmacist and a biomedical scientist. He completed his post doctoral fellowship at the University of Iowa with concentrations on signal transduction, inflammation and nociception. His clinical field of interest is musculoskeletal disorders. Currently, Dr. Goudarzi is directing the Division of Research and Development at Pharmin USA. He authored and coauthored highly influential scientific publications. His recent research work/invention (Nanocochleate) is published in the Journal of Nanomedicine (IF 6.40) and subsequently patented by the United States Patent and Trademark Office (2021). Dr. Goudarzi is the member of editorial board for the Journal of Current Medicine. Previously, he had an appointment as a chief pharmacist for Rite Aid Corporation, Bay Area, conducting and supervising patient assessments and pharmacotherapy.
Education & Training
- The University of Iowa, School of Medicine, Department of Pharmacology, IowaPostdoctoral Research Fellowship, Signal Transduction, 2001 - 2003
- National University, College of Management and Technology, San Jose, CaliforniaMaster of Business Administration, Entrepreneurship and Strategy, 1996 - 1998
- San Francisco General Hospital Medical Center, San Francisco, CaliforniaInternship, Internal Medicine , 1996 - 1998
- Tehran University of Medical Sciences, School of Pharmacy Pharmacy Doctorate, 1987 - 1993
Publications & Presentations
PubMed
- 18 citationsNeuroprotective phosphatidylserine liposomes alleviate depressive-like behavior related to stroke through neuroinflammation attenuation in the mouse hippocampusAlireza Partoazar, Zahra Seyyedian, Golnaz Zamanian, Partow Mirzaee Saffari, Ahad Muhammadnejad
Psychopharmacology. 2021-02-11 - 7 citationsPhosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronateMaryam Eskandarynasab, Amir Hossein Doustimotlagh, Nasrin Takzaree, Shahroo Etemad-Moghadam, Mojgan Alaeddini
Life Sciences. 2020-09-15 - 6 citationsNovel Osteoprotective Nanocochleate formulation: A dual combination therapy-Codelivery system against glucocorticoid induced osteoporosis.Maryam Eskandarynasab, Shahroo Etemad-Moghadam, Mojgan Alaeddini, Amir Hossein Doustimotlagh, Ali Nazeri
Nanomedicine. 2020-07-22
Journal Articles
- Beneficial effects of ROCEN (Topical Nano-arthrocen) on atopic dermatitis in miceRamin Goudarzi, Ahmad Reza Dehpour , Alireza Partoazar, BMC Complement Med Ther, 9/10/2021
- Novel osteoprotective nanocochleate formulation: A dual combination therapy-codelivery system against glucocorticoid induced osteoporosisRamin Goudarzi, Alireza Partoazar, Ahmad Reza Dehpour, Nanomedicine (IF 6.45), 10/29/2020
- Management of Osteoarthritis with Avocado/Soybean UnsaponifiablesChristiansen BA, Bhatti S, Goudarzi R, Emami S, Cartilage (IF 4.6), 1/6/2015
Other
- Nanostructures as Targeted Therapeutics for Combating Oral Bacterial DiseasesShima Afrasiabi, Alireza Partoazar and Ramin Goudarzi, Biomedicines (IF: 6.08)
https://www.mdpi.com/2227-9059/9/10/1435
https://www.mdpi.com/2227-9059/9/10/1435 - 10/10/2021 - Nanocochleate formulation and method of preparing the nanocochleate formulationR Goudarzi, ME Nassab, AR Dehpour, A Partoazar, US Patent App.
https://patents.justia.com/inventor/ramin-goudarzi
https://patents.justia.com/inventor/ramin-goudarzi - 1/21/2021
Office
Pharmin USA, LLC
www.pharminusa.com
Half Moon Bay, CA 94019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: